1. Home
  2. MXCT
  3. MXCT News

Latest MaxCyte Inc. (MXCT) News on August 3, 2025

MXCT

MT Newswires

2 months ago

MaxCyte Collaborates With Ori Biotech to Improve Cell Therapy Manufacturing

MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
MXCT

GlobeNewswire

2 months ago

MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies

MaxCyte, Inc. (MXCT): A Bull Case Theory
MXCT

Insider Monkey

3 months ago

MaxCyte, Inc. (MXCT): A Bull Case Theory

MXCT

GuruFocus.com

3 months ago

MaxCyte Inc (MXCT) Q1 2025 Earnings Call Highlights: Strong Revenue Alignment Amidst Growth ...

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
MXCT

Zacks

3 months ago

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates

MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance
MXCT

GlobeNewswire

3 months ago

MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance

MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025
MXCT

GlobeNewswire

4 months ago

MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025

Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT)
MXCT

Zacks

4 months ago

Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT)

With 66% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big guns
MXCT

Simply Wall St.

4 months ago

With 66% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big guns

Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround
MXCT

Zacks

4 months ago

Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround

MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know
MXCT

Zacks

4 months ago

MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know

MXCT

GuruFocus.com

5 months ago

MaxCyte Inc (MXCT) Q4 2024 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges

MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance
MXCT

GlobeNewswire

5 months ago

MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance

MXCT

MT Newswires

6 months ago

MaxCyte Licenses Cell-Engineering Technology to TG Therapeutics

MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
MXCT

GlobeNewswire

6 months ago

MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs

MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference
MXCT

GlobeNewswire

6 months ago

MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference

MXCT

MT Newswires

6 months ago

MaxCyte Acquires Gene Editing Analytics Company SeQure Dx

MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments
MXCT

GlobeNewswire

6 months ago

MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments

Investors push MaxCyte (LON:MXCT) 9.7% lower this week, company's increasing losses might be to blame
MXCT

Simply Wall St.

6 months ago

Investors push MaxCyte (LON:MXCT) 9.7% lower this week, company's increasing losses might be to blame

All You Need to Know About MaxCyte (MXCT) Rating Upgrade to Strong Buy
MXCT

Zacks

7 months ago

All You Need to Know About MaxCyte (MXCT) Rating Upgrade to Strong Buy

What Is MaxCyte, Inc.'s (LON:MXCT) Share Price Doing?
MXCT

Simply Wall St.

7 months ago

What Is MaxCyte, Inc.'s (LON:MXCT) Share Price Doing?

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
MXCT

GlobeNewswire

7 months ago

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

MaxCyte, Inc.'s (LON:MXCT) Intrinsic Value Is Potentially 72% Above Its Share Price
MXCT

Simply Wall St.

7 months ago

MaxCyte, Inc.'s (LON:MXCT) Intrinsic Value Is Potentially 72% Above Its Share Price

MaxCyte Announces Retirement of Board Member Art Mandell
MXCT

GlobeNewswire

7 months ago

MaxCyte Announces Retirement of Board Member Art Mandell

MXCT

MT Newswires

8 months ago

MaxCyte Reduces 15% of Workforce, Raises 2024 Revenue Guidance

MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance
MXCT

GlobeNewswire

8 months ago

MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance

This MaxCyte Insider Increased Their Holding In The Last Year
MXCT

Simply Wall St.

8 months ago

This MaxCyte Insider Increased Their Holding In The Last Year

MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
MXCT

GlobeNewswire

9 months ago

MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics

MXCT

GuruFocus.com

9 months ago

MaxCyte Inc (MXCT) Q3 2024 Earnings Call Highlights: Strong Core Revenue Growth Amidst Market ...

MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates
MXCT

Zacks

9 months ago

MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates

MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance
MXCT

GlobeNewswire

9 months ago

MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance

MaxCyte to Participate in Two Upcoming Investor Conferences
MXCT

GlobeNewswire

9 months ago

MaxCyte to Participate in Two Upcoming Investor Conferences

MaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 65% of the company
MXCT

Simply Wall St.

9 months ago

MaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 65% of the company

MaxCyte (MXCT) Upgraded to Strong Buy: What Does It Mean for the Stock?
MXCT

Zacks

10 months ago

MaxCyte (MXCT) Upgraded to Strong Buy: What Does It Mean for the Stock?

MaxCyte Appoints Cynthia Collins to its Board of Directors
MXCT

GlobeNewswire

10 months ago

MaxCyte Appoints Cynthia Collins to its Board of Directors

MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024
MXCT

GlobeNewswire

10 months ago

MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024

MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
MXCT

GlobeNewswire

10 months ago

MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer

MXCT

GuruFocus.com

10 months ago

MaxCyte Inc (MXCT) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Core Challenges

We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth
MXCT

Simply Wall St.

10 months ago

We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

MaxCyte and Kamau Therapeutics sign platform license agreement
MXCT

Pharmaceutical Technology

a year ago

MaxCyte and Kamau Therapeutics sign platform license agreement

MXCT

MT Newswires

a year ago

MaxCyte, Kamau Therapeutics Partner for Flow Electroporation Technology

MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
MXCT

GlobeNewswire

a year ago

MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases

MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference
MXCT

GlobeNewswire

a year ago

MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference

MaxCyte (LON:MXCT) shareholders have earned a 22% CAGR over the last five years
MXCT

Simply Wall St.

a year ago

MaxCyte (LON:MXCT) shareholders have earned a 22% CAGR over the last five years

MaxCyte, Inc. (MXCT) Reports Q2 Loss, Tops Revenue Estimates
MXCT

Zacks

a year ago

MaxCyte, Inc. (MXCT) Reports Q2 Loss, Tops Revenue Estimates

MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance
MXCT

GlobeNewswire

a year ago

MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance

MaxCyte (MXCT) is on the Move, Here's Why the Trend Could be Sustainable
MXCT

Zacks

a year ago

MaxCyte (MXCT) is on the Move, Here's Why the Trend Could be Sustainable

MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024
MXCT

GlobeNewswire

a year ago

MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024

President of MaxCyte Maher Masoud Buys More Stock
MXCT

Simply Wall St.

a year ago

President of MaxCyte Maher Masoud Buys More Stock

Does MaxCyte (MXCT) Have the Potential to Rally 85% as Wall Street Analysts Expect?
MXCT

Zacks

a year ago

Does MaxCyte (MXCT) Have the Potential to Rally 85% as Wall Street Analysts Expect?

Recent Price Trend in MaxCyte (MXCT) is Your Friend, Here's Why
MXCT

Zacks

a year ago

Recent Price Trend in MaxCyte (MXCT) is Your Friend, Here's Why

Insider Buying: President and CEO Maher Masoud Acquires 100,000 Shares of MaxCyte Inc (MXCT)
MXCT

GuruFocus.com

a year ago

Insider Buying: President and CEO Maher Masoud Acquires 100,000 Shares of MaxCyte Inc (MXCT)

MXCT

MT Newswires

a year ago

Maxcyte Insider Bought Shares Worth $489,066, According to a Recent SEC Filing

MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
MXCT

GlobeNewswire

a year ago

MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference

With 64% ownership of the shares, MaxCyte, Inc. (LON:MXCT) is heavily dominated by institutional owners
MXCT

Simply Wall St.

a year ago

With 64% ownership of the shares, MaxCyte, Inc. (LON:MXCT) is heavily dominated by institutional owners

MXCT

MT Newswires

a year ago

MaxCyte Signs License Deal With Legend Biotech for Cell Therapy Program

MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
MXCT

GlobeNewswire

a year ago

MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development

MaxCyte, Inc. (NASDAQ:MXCT) Q1 2024 Earnings Call Transcript
MXCT

Insider Monkey

a year ago

MaxCyte, Inc. (NASDAQ:MXCT) Q1 2024 Earnings Call Transcript

MXCT

MT Newswires

a year ago

MaxCyte Shares Rise Sharply After Q1 Results Beat

MXCT

Thomson Reuters StreetEvents

a year ago

Q1 2024 MaxCyte Inc Earnings Call

MXCT

GuruFocus.com

a year ago

MaxCyte Inc (MXCT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ...

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
MXCT

Zacks

a year ago

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates

MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance
MXCT

GlobeNewswire

a year ago

MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance

We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth
MXCT

Simply Wall St.

a year ago

We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
MXCT

GlobeNewswire

a year ago

MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024

MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
MXCT

GlobeNewswire

a year ago

MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)

Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term
MXCT

Simply Wall St.

a year ago

Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term

MaxCyte, Inc. (LON:MXCT) Just Reported And Analysts Have Been Cutting Their Estimates
MXCT

Simply Wall St.

a year ago

MaxCyte, Inc. (LON:MXCT) Just Reported And Analysts Have Been Cutting Their Estimates

MaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call Transcript
MXCT

Insider Monkey

a year ago

MaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call Transcript

MaxCyte's (LON:MXCT) investors will be pleased with their notable 68% return over the last five years
MXCT

Simply Wall St.

a year ago

MaxCyte's (LON:MXCT) investors will be pleased with their notable 68% return over the last five years

11 Oversold Healthcare Stocks To Buy Right Now
MXCT

Insider Monkey

a year ago

11 Oversold Healthcare Stocks To Buy Right Now

MaxCyte Inc (MXCT) Reports Mixed Financial Results for Q4 and Full Year 2023
MXCT

GuruFocus.com

a year ago

MaxCyte Inc (MXCT) Reports Mixed Financial Results for Q4 and Full Year 2023

MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
MXCT

GlobeNewswire

a year ago

MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance

MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
MXCT

GlobeNewswire

a year ago

MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results

MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
MXCT

GlobeNewswire

a year ago

MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences

Dine Brands Global Named to Newsweek’s America’s Greatest Workplaces for Diversity 2024
MXCT

Business Wire

2 years ago

Dine Brands Global Named to Newsweek’s America’s Greatest Workplaces for Diversity 2024

We're Not Very Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate
MXCT

Simply Wall St.

2 years ago

We're Not Very Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers
MXCT

GlobeNewswire

2 years ago

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers

The Zacks Analyst Blog Highlights Simmons First National, Independent Bank, S&P Global, HBT Financial and Canadian National Railway
MXCT

Zacks

2 years ago

The Zacks Analyst Blog Highlights Simmons First National, Independent Bank, S&P Global, HBT Financial and Canadian National Railway

MXCT

Associated Press Finance

2 years ago

Dynex Capital: Q4 Earnings Snapshot

Open Lending Partners with Automatic to Expand Indirect Lending Opportunities
MXCT

Business Wire

2 years ago

Open Lending Partners with Automatic to Expand Indirect Lending Opportunities

Dynex Capital, Inc. Announces Fourth Quarter and Full Year 2023 Results
MXCT

Business Wire

2 years ago

Dynex Capital, Inc. Announces Fourth Quarter and Full Year 2023 Results

MXCT

Investing.com

2 years ago

Dollar edges higher ahead of Fed meeting, payrolls

5 Stocks to Watch on Their Recent Dividend Hikes
MXCT

Zacks

2 years ago

5 Stocks to Watch on Their Recent Dividend Hikes

MXCT

Investing.com

2 years ago

Dollar steadies ahead of key inflation data; euro slips post ECB

Weave Communications, Inc. (WEAV) Moves 5.7% Higher: Will This Strength Last?
MXCT

Zacks

2 years ago

Weave Communications, Inc. (WEAV) Moves 5.7% Higher: Will This Strength Last?

Tourmaline Bio Announces Pricing of Public Offering of Common Stock
MXCT

GlobeNewswire

2 years ago

Tourmaline Bio Announces Pricing of Public Offering of Common Stock

First Community Bankshares Full Year 2023 Earnings: In Line With Expectations
MXCT

Simply Wall St.

2 years ago

First Community Bankshares Full Year 2023 Earnings: In Line With Expectations

Zacks Industry Outlook Highlights Frontier Communications and Weave Communications
MXCT

Zacks

2 years ago

Zacks Industry Outlook Highlights Frontier Communications and Weave Communications

MXCT

GuruFocus.com

2 years ago

First Community Bankshares Inc Reports Mixed Results Amid Litigation Expenses

With 60% institutional ownership, Ares Acquisition Corporation II (NYSE:AACT) is a favorite amongst the big guns
MXCT

Simply Wall St.

2 years ago

With 60% institutional ownership, Ares Acquisition Corporation II (NYSE:AACT) is a favorite amongst the big guns

Global Ship Lease (GSL) Stock Sinks As Market Gains: What You Should Know
MXCT

Zacks

2 years ago

Global Ship Lease (GSL) Stock Sinks As Market Gains: What You Should Know

First Community Bancshares (FCBC) Q4 Earnings and Revenues Surpass Estimates
MXCT

Zacks

2 years ago

First Community Bancshares (FCBC) Q4 Earnings and Revenues Surpass Estimates

MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
MXCT

GlobeNewswire

2 years ago

MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

Genco Highlights Steps the Company Is Taking to Drive Sustainable, Long-Term Shareholder Value
MXCT

GlobeNewswire

2 years ago

Genco Highlights Steps the Company Is Taking to Drive Sustainable, Long-Term Shareholder Value

Is Quanex Building Products Corporation (NYSE:NX) Trading At A 22% Discount?
MXCT

Simply Wall St.

2 years ago

Is Quanex Building Products Corporation (NYSE:NX) Trading At A 22% Discount?

Ameresco Announces Completion of 27-Megawatt Solar Farm in Village of DePue, IL
MXCT

Business Wire

2 years ago

Ameresco Announces Completion of 27-Megawatt Solar Farm in Village of DePue, IL

MainStay CBRE Global Infrastructure Megatrends Term Fund (NYSE: MEGI) Declares Monthly Distribution for January 2024 and Availability of 19(a) Notice
MXCT

PR Newswire

2 years ago

MainStay CBRE Global Infrastructure Megatrends Term Fund (NYSE: MEGI) Declares Monthly Distribution for January 2024 and Availability of 19(a) Notice

Returns On Capital At Ameresco (NYSE:AMRC) Paint A Concerning Picture
MXCT

Simply Wall St.

2 years ago

Returns On Capital At Ameresco (NYSE:AMRC) Paint A Concerning Picture

Okta (OKTA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
MXCT

Zacks

2 years ago

Okta (OKTA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Share on Social Networks: